Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
845 stopped studies mapped to Malignant Bone Marrow Neoplasm and descendants · 88% state a reason
Over the 845 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04551066 | To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With… | Phase 3 | terminated | Sep 16, 2020 | Incyte Corporation | The study was terminated due to futility. | Efficacy / futility |
| NCT04623216 | Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of… | Phase 1 / Phase 2 | terminated | Nov 10, 2020 | Novartis Pharmaceuticals | Study was stopped following a strategic decision from the Sponsor. It was not based on any safety… | Safety / toxicity |
| NCT04678336 | CD123 Redirected T Cells for AML in Pediatric Subjects | Phase 1 | terminated | Dec 21, 2020 | University of Pennsylvania | Administrative reasons | Other (stated, no rule matched) |
| NCT03940352 | HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia… | Phase 1 | terminated | May 7, 2019 | Novartis Pharmaceuticals | Business decision | Sponsor / business decision |
| NCT04702425 | VOB560-MIK665 Combination First in Human Trial in Patients With Hematological… | Phase 1 | terminated | Jan 8, 2021 | Novartis Pharmaceuticals | Business reasons | Sponsor / business decision |
| NCT04551053 | To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With… | Phase 3 | terminated | Sep 16, 2020 | Incyte Corporation | The study was terminated due to futility. | Efficacy / futility |
| NCT05148234 | BMS-986253 in Myelodysplastic Syndromes | Phase 1 / Phase 2 | terminated | Dec 8, 2021 | National Cancer Institute (NCI) | Company closed the trial. | Sponsor / business decision |
| NCT05358808 | ACHIEVE - Efficacy and Effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded…(ACHIEVE) | Phase 2 | terminated | May 3, 2022 | TC Biopharm | The Trial was early terminated due to deficiencies in the Achieve Protocol: V8.0 dated 19 January… | Other (stated, no rule matched) |
| NCT05168202 | A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and… | Phase 1 | terminated | Dec 23, 2021 | Bristol-Myers Squibb | Business objectives have changed | Sponsor / business decision |
| NCT05961839 | Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic… | Phase 1 | terminated | Jul 27, 2023 | Schrödinger, Inc. | Company decision | Sponsor / business decision |
| NCT03860844 | Isatuximab in Combination With Chemotherapy in Pediatric Patients With…(ISAKIDS) | Phase 2 | terminated | Mar 4, 2019 | Sanofi | Study was prematurely stopped due to sponsor decision (stage 2 efficacy criteria not met); not due… | Safety / toxicity |
| NCT02438761 | PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid…(5) | Phase 2 | terminated | May 8, 2015 | Institut Curie | No objective response was observed at the first step. The treatment was considered ineffective,… | Other (stated, no rule matched) |
| NCT04951778 | Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With… | Phase 1 | terminated | Jul 7, 2021 | Celgene | Efficacy endpoint met; however, overall experimental dosing regimen is not considered optimal to… | Efficacy / futility |
| NCT03769532 | MRD-guided Treatment in NPM1mut AML Patients(PEMAZA) | Phase 2 | terminated | Dec 7, 2018 | Technische Universität Dresden | Feasibility | Other (stated, no rule matched) |
| NCT06679582 | Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With… | Phase 1 / Phase 2 | terminated | Nov 7, 2024 | Sutro Biopharma, Inc. | Terminated Early | Other (stated, no rule matched) |
| NCT06508489 | A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in… | Phase 1 / Phase 2 | terminated | Jul 18, 2024 | Sanofi | Early discontinuation based on strategic sponsor decision not driven by any safety concerns | Safety / toxicity |
| NCT04849910 | Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein,… | Phase 1 / Phase 2 | terminated | Apr 19, 2021 | Vor Biopharma | Lack of Funding | Funding |
| NCT05817058 | First-in-Human Dose Escalation Study of AFM28 in Patients With Relapsed/Refractory Acute… | Phase 1 | terminated | Apr 18, 2023 | Affimed GmbH | As decided by sponsor | Other (stated, no rule matched) |
| NCT05209152 | AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic… | Phase 1 | terminated | Jan 26, 2022 | Amgen | Sponsor decision, unrelated to safety | Safety / toxicity |
| NCT05968170 | TCRαβ/CD19 Depletion of Stem Cell Grafts for Transplant | N/A | withdrawn | Aug 1, 2023 | Neena Kapoor, M.D. | No funding available. | Funding |
| NCT04789408 | Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia | Phase 1 | terminated | Mar 9, 2021 | Kite, A Gilead Company | Study was terminated due to futility | Efficacy / futility |
| NCT03333486 | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell… | Phase 2 | terminated | Nov 7, 2017 | Roswell Park Cancer Institute | Futility analysis determined closure | Efficacy / futility |
| NCT01688011 | Connect® Myeloid Disease Registry | — | terminated | Sep 19, 2012 | Celgene | Business objectives have changed | Sponsor / business decision |
| NCT05153330 | Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With… | Phase 1 | terminated | Dec 10, 2021 | Biomea Fusion Inc. | Biomea Fusion, Inc., is no longer pursuing oncology indications for BMF-219. No safety concerns or… | Safety / toxicity |
| NCT04103645 | Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib… | Phase 2 | terminated | Sep 25, 2019 | Weill Medical College of Cornell University | Low accrual | Enrollment / accrual |
| NCT05442580 | CART-38 in Adult AML and MM Patients | Phase 1 | terminated | Jul 5, 2022 | University of Pennsylvania | Administrative decision | Other (stated, no rule matched) |
| NCT05521087 | A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and… | Phase 1 | withdrawn | Aug 30, 2022 | Janssen Research & Development, LLC | Business Decision | Sponsor / business decision |
| NCT03724084 | Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute… | Phase 1 / Phase 2 | terminated | Oct 30, 2018 | National Cancer Institute (NCI) | Other - Study agent no longer available | Other (stated, no rule matched) |
| NCT02848001 | A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid… | Phase 1 | terminated | Jul 28, 2016 | Celgene | Trial terminated because of lack of efficacy in the short term acute phase. | Efficacy / futility |
| NCT05248685 | Optimized Dual CD33/CLL1 CAR T Cells in Subjects With Refractory or Relapsed Acute… | Phase 1 | withdrawn | Feb 21, 2022 | Beijing Boren Hospital | no patients | Other (stated, no rule matched) |
| NCT06128044 | CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With…(AMpLify) | Phase 1 | terminated | Nov 13, 2023 | Caribou Biosciences, Inc. | Sponsor Decision - Pipeline Reprioritization | Sponsor / business decision |
| NCT01751425 | Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual… | Phase 1 | terminated | Dec 18, 2012 | M.D. Anderson Cancer Center | Per PI Request. 2) No additional benefit was noted with the addition of Ruxolitinib. | Other (stated, no rule matched) |
| NCT04789655 | Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia | Phase 1 | terminated | Mar 9, 2021 | Celgene | Business objectives have changed | Sponsor / business decision |
| NCT06449482 | Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not… | Phase 1 / Phase 2 | terminated | Jun 10, 2024 | Institute of Hematology & Blood Diseases Hospital, China | The number of participants in the study did not meet expectations | Other (stated, no rule matched) |
| NCT06572631 | Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for… | Phase 1 | withdrawn | Aug 27, 2024 | City of Hope Medical Center | cprmc withdrawn | Other (stated, no rule matched) |
| NCT04752163 | DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of… | Phase 1 / Phase 2 | terminated | Feb 12, 2021 | M.D. Anderson Cancer Center | supporting/funding source decided to de-prioritize and stop development of DS-1594 | Funding |
| NCT03537599 | Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute… | Phase 1 / Phase 2 | terminated | May 25, 2018 | Sumithira Vasu | Poor acccrual | Other (stated, no rule matched) |
| NCT05447663 | A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute… | Phase 1 / Phase 2 | terminated | Jul 7, 2022 | Novartis Pharmaceuticals | Study has been stopped following the strategic decision from the Sponsor. Not based on any safety… | Safety / toxicity |
| NCT03286114 | Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab | Phase 1 | terminated | Sep 18, 2017 | University of Michigan Rogel Cancer Center | Lack of patient population | Other (stated, no rule matched) |
| NCT03576547 | Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or… | Phase 1 / Phase 2 | terminated | Jul 3, 2018 | M.D. Anderson Cancer Center | The study was terminated early due to slow accrual and low level of interest both by the sponsor… | Enrollment / accrual |
| NCT05038644 | XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic… | Phase 1 | terminated | Sep 9, 2021 | Ehab L Atallah | Drug expired May 31, 2024. | Other (stated, no rule matched) |
| NCT01532635 | A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched… | Phase 2 | terminated | Feb 14, 2012 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Slow accrual | Enrollment / accrual |
| NCT03560908 | Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT… | Phase 1 | withdrawn | Jun 18, 2018 | Institute of Hematology & Blood Diseases Hospital, China | No enough eligable participants enrolled | Enrollment / accrual |
| NCT05595135 | Mobile Intervention to Improve Adherence of Oral Anti-cancer Medications Among Acute… | N/A | withdrawn | Oct 26, 2022 | Thomas Jefferson University | staffing | Other (stated, no rule matched) |
| NCT05766514 | Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs.… | Phase 2 | withdrawn | Mar 13, 2023 | University of Florida | Study disapproved by internal scientific review committee on re-review; study will no longer move… | Other (stated, no rule matched) |
| NCT03016130 | Comparing Two Diets in Patients Undergoing HSCT or Remission Induction Chemo for Acute… | Phase 3 | terminated | Jan 10, 2017 | University of Florida | Interim analysis determined that study reached a safety stopping rule | Safety / toxicity |
| NCT04185428 | Investigating Integrative Therapies for Symptom Management in Adults With Acute Leukemia | N/A | terminated | Dec 4, 2019 | University of Florida | The PIs left the institution. | Other (stated, no rule matched) |
| NCT03038230 | MCLA-117 in Acute Myelogenous Leukemia | Phase 1 | terminated | Jan 31, 2017 | Merus B.V. | strategic considerations | Sponsor / business decision |
| NCT03615105 | Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA… | Phase 2 | terminated | Aug 3, 2018 | Memorial Sloan Kettering Cancer Center | Low accrual | Enrollment / accrual |
| NCT05079230 | Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in…(ENHANCE-3) | Phase 3 | terminated | Oct 15, 2021 | Gilead Sciences | Study was terminated due to futility | Efficacy / futility |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Oct 21, 2025source: clinicaltrials